Evidence map›Paper›PMID 36335980›Full record

ArticleESC heart failure2023

Multimodality assessments of wild-type transthyretin cardiac amyloidosis with no ventricular hypertrophy.

Takuma Iwaya, Atsushi Okada, Emi Tateishi, Yasutoshi Ohta, Yoshiaki Morita, Keiko Ohta-Ogo, Chisato Izumi

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Takuma IwayaDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.
Atsushi OkadaDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.
Emi TateishiDepartment of Radiology, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.
Yasutoshi OhtaDepartment of Radiology, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.
Yoshiaki MoritaDepartment of Radiology, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.
Keiko Ohta-OgoDepartment of Pathology, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.
Chisato IzumiDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While patients with transthyretin cardiac amyloidosis (ATTR-CA) typically present with concentric or asymmetric hypertrophy, a small percentage of ATTR-CA is known to present with 'atypical' cardiac morphologies such as eccentric hypertrophy or even no hypertrophy. However, detailed report of multimodality assessments of ATTR-CA with no ventricular hypertrophy is lacking. Herein, we report detailed multimodality assessments of an 81-year-old Japanese woman with heart failure and history of carpal tunnel syndrome and lumbar canal stenosis, presenting no ventricular hypertrophy and negative

Indexed as

Amyloid Neuropathies, FamilialCardiomyopathiesAged, 80 and overFemaleHumansPrealbuminRadionuclide ImagingPrealbuminAmyloid cardiomyopathyCardiovascular magnetic resonanceFalse negativeHeart failurePyrophosphate scintigraphyTafamidis

Identifiers

PMID36335980
PMCPMC10053176

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.